LEXINGTON, Mass., Feb. 1, 2024
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company
focused on the development of emavusertib (CA-4948), an orally
available, small molecule IRAK4 inhibitor, today announced that the
Company will release its fourth quarter 2023 financial results on
Thursday, February 8, 2024,
at 8:00 a.m. ET. Management will host a conference call
at 8:30 a.m. ET.
To access the live conference call, please dial (888)-346-6389
from the United States or (412)-317-5252 from other
locations, shortly before 8:30 a.m. ET. The conference call
can also be accessed on the Curis website
at www.curis.com in the 'Investors' section. A replay of
the conference call will be available on the Curis website shortly
after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor.
Emavusertib is currently undergoing testing in the Phase 1/2
TakeAim Lymphoma study in patients with relapsed/refractory Primary
Central Nervous System Lymphoma (PCNSL) in combination with the BTK
inhibitor ibrutinib, and as a monotherapy in the Phase 1/2 TakeAim
Leukemia study in patients with relapsed/refractory acute myeloid
leukemia (AML) and relapsed/refractory high risk myelodysplastic
syndrome (hrMDS), both of which have received Orphan Drug
Designation from the U.S. Food and Drug Administration. Emavusertib
is also being evaluated as a frontline combination therapy with
azacitidine and venetoclax in patents with AML. Curis, through its
2015 collaboration with Aurigene, has the exclusive license to
emavusertib (CA-4948). Curis licensed its rights to Erivedge® to
Genentech, a member of the Roche Group, under which they are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website
at www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-release-fourth-quarter-2023-financial-results-and-hold-conference-call-on-february-8-2024-302049568.html
SOURCE Curis, Inc.